Cargando…

Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia

Early initiation of oseltamivir within 48 h to 5 days from illness onset has been associated with improved survival among patients with community-acquired influenza pneumonia. Delay of hospitalization limits early treatment and the survival of patients. To date, the effects of early oseltamivir init...

Descripción completa

Detalles Bibliográficos
Autores principales: Kositpantawong, Narongdet, Surasombatpattana, Smonrapat, Siripaitoon, Pisud, Kanchanasuwan, Siripen, Hortiwakul, Thanaporn, Charernmak, Boonsri, Nwabor, Ozioma Forstinus, Chusri, Sarunyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673668/
https://www.ncbi.nlm.nih.gov/pubmed/34910777
http://dx.doi.org/10.1371/journal.pone.0261411
_version_ 1784615497514352640
author Kositpantawong, Narongdet
Surasombatpattana, Smonrapat
Siripaitoon, Pisud
Kanchanasuwan, Siripen
Hortiwakul, Thanaporn
Charernmak, Boonsri
Nwabor, Ozioma Forstinus
Chusri, Sarunyou
author_facet Kositpantawong, Narongdet
Surasombatpattana, Smonrapat
Siripaitoon, Pisud
Kanchanasuwan, Siripen
Hortiwakul, Thanaporn
Charernmak, Boonsri
Nwabor, Ozioma Forstinus
Chusri, Sarunyou
author_sort Kositpantawong, Narongdet
collection PubMed
description Early initiation of oseltamivir within 48 h to 5 days from illness onset has been associated with improved survival among patients with community-acquired influenza pneumonia. Delay of hospitalization limits early treatment and the survival of patients. To date, the effects of early oseltamivir initiation within 24 hours from admission on patient mortality has remained unknown. This retrospective study reviewed and analyzed the clinical and non-clinical outcomes of 143 patients, with community-acquired influenza pneumonia, who received oseltamivir within 24 h (group A) and after 24 h (group B) from admission. Among the patients, 82 (57.3%) received oseltamivir within 24 h while 61 (42.7%) received oseltamivir after 24 h. The median time from symptom onset to admission for group A and group B was not statistically significant (P < 0.001). The 14-day mortality rate was 9% and 23% for group A and B, respectively (P = 0.03), while the 30-day mortality were 15% and 30% for group A and B, respectively (P = 0.05). Administration of oseltamivir within 24 h significantly affected 30-day mortality rates (adjust OR: 0.14, 95% CI: 0.47–0.04, P < 0.01), particularly among patients with respiratory failure at admission (adjust OR: 0.08, 95% CI: 0+.30–0.06, P < 0.01). Survival analysis of patient with influenza pneumonia and respiratory failure at admission demonstrated significant difference between those who received oseltamivir within and after 24 h (P = 0.002). The results indicated that early oseltamivir initiation within 24 h improved the survival outcome mainly among those with respiratory failure at admission.
format Online
Article
Text
id pubmed-8673668
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-86736682021-12-16 Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia Kositpantawong, Narongdet Surasombatpattana, Smonrapat Siripaitoon, Pisud Kanchanasuwan, Siripen Hortiwakul, Thanaporn Charernmak, Boonsri Nwabor, Ozioma Forstinus Chusri, Sarunyou PLoS One Research Article Early initiation of oseltamivir within 48 h to 5 days from illness onset has been associated with improved survival among patients with community-acquired influenza pneumonia. Delay of hospitalization limits early treatment and the survival of patients. To date, the effects of early oseltamivir initiation within 24 hours from admission on patient mortality has remained unknown. This retrospective study reviewed and analyzed the clinical and non-clinical outcomes of 143 patients, with community-acquired influenza pneumonia, who received oseltamivir within 24 h (group A) and after 24 h (group B) from admission. Among the patients, 82 (57.3%) received oseltamivir within 24 h while 61 (42.7%) received oseltamivir after 24 h. The median time from symptom onset to admission for group A and group B was not statistically significant (P < 0.001). The 14-day mortality rate was 9% and 23% for group A and B, respectively (P = 0.03), while the 30-day mortality were 15% and 30% for group A and B, respectively (P = 0.05). Administration of oseltamivir within 24 h significantly affected 30-day mortality rates (adjust OR: 0.14, 95% CI: 0.47–0.04, P < 0.01), particularly among patients with respiratory failure at admission (adjust OR: 0.08, 95% CI: 0+.30–0.06, P < 0.01). Survival analysis of patient with influenza pneumonia and respiratory failure at admission demonstrated significant difference between those who received oseltamivir within and after 24 h (P = 0.002). The results indicated that early oseltamivir initiation within 24 h improved the survival outcome mainly among those with respiratory failure at admission. Public Library of Science 2021-12-15 /pmc/articles/PMC8673668/ /pubmed/34910777 http://dx.doi.org/10.1371/journal.pone.0261411 Text en © 2021 Kositpantawong et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kositpantawong, Narongdet
Surasombatpattana, Smonrapat
Siripaitoon, Pisud
Kanchanasuwan, Siripen
Hortiwakul, Thanaporn
Charernmak, Boonsri
Nwabor, Ozioma Forstinus
Chusri, Sarunyou
Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia
title Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia
title_full Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia
title_fullStr Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia
title_full_unstemmed Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia
title_short Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia
title_sort outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673668/
https://www.ncbi.nlm.nih.gov/pubmed/34910777
http://dx.doi.org/10.1371/journal.pone.0261411
work_keys_str_mv AT kositpantawongnarongdet outcomesofearlyoseltamivirtreatmentforhospitalizedadultpatientswithcommunityacquiredinfluenzapneumonia
AT surasombatpattanasmonrapat outcomesofearlyoseltamivirtreatmentforhospitalizedadultpatientswithcommunityacquiredinfluenzapneumonia
AT siripaitoonpisud outcomesofearlyoseltamivirtreatmentforhospitalizedadultpatientswithcommunityacquiredinfluenzapneumonia
AT kanchanasuwansiripen outcomesofearlyoseltamivirtreatmentforhospitalizedadultpatientswithcommunityacquiredinfluenzapneumonia
AT hortiwakulthanaporn outcomesofearlyoseltamivirtreatmentforhospitalizedadultpatientswithcommunityacquiredinfluenzapneumonia
AT charernmakboonsri outcomesofearlyoseltamivirtreatmentforhospitalizedadultpatientswithcommunityacquiredinfluenzapneumonia
AT nwaboroziomaforstinus outcomesofearlyoseltamivirtreatmentforhospitalizedadultpatientswithcommunityacquiredinfluenzapneumonia
AT chusrisarunyou outcomesofearlyoseltamivirtreatmentforhospitalizedadultpatientswithcommunityacquiredinfluenzapneumonia